Mirati Therapeutics, Inc. (MRTX) Stock Analysis

Mirati Therapeutics, Inc. (MRTX) Healthcare & Pipeline Overview

Mirati Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in oncology, particularly known for its KRAS inhibitor programs targeting non-small cell lung, colorectal, and pancreatic cancers. The company's focus on innovative therapies positions it within a competitive landscape of personalized medicine.

What Is the Investment Thesis for MRTX?

The company's lead candidate, adagrasib (MRTX849), targets the KRAS G12C mutation, prevalent in NSCLC, colorectal, and pancreatic cancers, offering significant market potential. Positive clinical trial data and potential regulatory approvals for adagrasib could drive substantial revenue growth. Sitravatinib, another key asset, is in Phase 3 trials and could further diversify the company's revenue streams. However, the company's high profit margin of -5957.4% indicates substantial ongoing R&D expenses, and competition in the oncology space poses a risk. Successful commercialization and pipeline expansion are critical for long-term value creation. Upcoming clinical trial results and regulatory milestones serve as key catalysts.

Based on FMP financials and quantitative analysis

MRTX Key Highlights

Market Cap of $4.12B reflects investor confidence in Mirati's pipeline and potential for future growth in the oncology market.

• Gross Margin of 95.2% indicates strong pricing power and efficient manufacturing processes for its products.
• Beta of 0.77 suggests lower volatility compared to the overall market, potentially making it a more stable investment.
• Focus on KRAS inhibitors positions Mirati at the forefront of targeted cancer therapies, addressing a significant unmet medical need.
• Collaboration with BeiGene, Ltd. expands Mirati's global reach and commercialization capabilities for Sitravatinib.

Who Are MRTX's Competitors?

MRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MRTX's Key Strengths?

Innovative KRAS inhibitor technology.

• Strong pipeline of product candidates.
• Experienced management team.
• Strategic collaborations with leading companies.

What Are MRTX's Weaknesses?

High R&D expenses.

• Reliance on clinical trial success.
• Competition from other biotechnology and pharmaceutical companies.
• Negative profit margin.

What Could Drive MRTX Stock Higher?

Data readouts from ongoing clinical trials of adagrasib in various cancer types.

• Potential regulatory submissions and approvals for adagrasib and sitravatinib.
• Expansion of strategic collaborations and partnerships.
• Advancement of preclinical programs into clinical development.

What Are the Key Risks for MRTX?

Negative return on equity (-61.9%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $3.4M recently.
• Clinical trial failures or setbacks.
• Regulatory delays or rejections.
• Competition from other biotechnology and pharmaceutical companies.
• High R&D expenses and cash burn.
• Patent expirations and loss of exclusivity.

What Are the Growth Opportunities for MRTX?

• Expansion of Adagrasib (MRTX849) Indications: Adagrasib, a KRAS G12C inhibitor, has the potential to expand beyond NSCLC to other cancer types with the KRAS G12C mutation, such as colorectal and pancreatic cancers. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
• Advancement of Sitravatinib: Sitravatinib, a spectrum-selective kinase inhibitor, is currently in Phase 3 clinical trials for NSCLC. Positive trial results and subsequent regulatory approval could provide a significant revenue stream. The NSCLC market is substantial, and a successful commercial launch of Sitravatinib could contribute significantly to Mirati's growth. Timeline: Phase 3 trial results expected within the next year, with potential regulatory submission shortly after.
• Development of KRAS G12D Inhibitor Program: Mirati's preclinical KRAS G12D inhibitor program represents a future growth opportunity. KRAS G12D is another common KRAS mutation, and a successful inhibitor could address a significant unmet need. The market potential for KRAS G12D inhibitors is substantial, offering long-term growth prospects. Timeline: Preclinical development ongoing, with potential for clinical trials in the next 2-3 years.
• Strategic Collaborations and Partnerships: Mirati can pursue strategic collaborations and partnerships to expand its pipeline and commercial reach. Collaborations with other biotechnology and pharmaceutical companies can provide access to new technologies, funding, and markets. These partnerships can accelerate the development and commercialization of Mirati's product candidates. Timeline: Ongoing, with potential for new collaborations in the near term.
• Expansion into New Therapeutic Areas: While Mirati is primarily focused on KRAS inhibitors, the company can explore opportunities to expand into other therapeutic areas within oncology. This could involve developing therapies for other genetic drivers of cancer or exploring new approaches such as immunotherapy. Diversifying its pipeline can reduce risk and create new growth opportunities. Timeline: Long-term, with potential for new programs in the next 3-5 years.

What Are MRTX's Competitive Advantages?

• Proprietary KRAS inhibitor technology provides a competitive advantage.
• Strong patent protection for its product candidates.
• Expertise in developing targeted cancer therapies.
• Established collaborations with leading research institutions and pharmaceutical companies.

What Does MRTX Do?

Founded in 1995 and headquartered in San Diego, California, Mirati Therapeutics, Inc. is dedicated to transforming the lives of patients with cancer by developing innovative therapies that target the genetic and immunological drivers of the disease. The company's evolution has been marked by a commitment to addressing unmet needs in oncology, particularly in areas with limited treatment options. Mirati's pipeline features a range of product candidates, including MRTX849 (adagrasib), a KRAS G12C inhibitor, which is in Phase 1/2 clinical trials for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers. Additionally, the company is developing Sitravatinib, an investigational spectrum-selective kinase inhibitor currently in Phase 3 clinical trials for NSCL cancer treatment. Furthermore, Mirati has a KRAS G12D inhibitor program in preclinical development, expanding its focus on KRAS mutations. The company collaborates with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib, enhancing its global reach. Mirati's strategic focus on precision oncology and targeted therapies aims to provide more effective and personalized treatment options for cancer patients.

What Products and Services Does MRTX Offer?

• Develops targeted therapies for cancer.
• Focuses on addressing genetic and immunological promoters of cancer.
• Creates KRAS inhibitors to treat non-small cell lung, colorectal, and pancreatic cancers.
• Develops spectrum-selective kinase inhibitors for cancer treatment.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Collaborates with other companies to develop and commercialize its therapies.
• Engages in preclinical research to discover new cancer treatments.

How Does MRTX Make Money?

• Develops and patents novel cancer therapies.
• Conducts clinical trials to gain regulatory approval.
• Commercializes approved therapies directly or through partnerships.
• Generates revenue through sales of its approved therapies and licensing agreements.

What Industry Does MRTX Operate In?

Mirati Therapeutics operates within the dynamic and competitive biotechnology industry, specifically focused on oncology. The industry is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Mirati's focus on KRAS inhibitors places it in a competitive landscape with other companies developing targeted therapies. Key trends include personalized medicine, immunotherapy, and gene editing. The company's success depends on its ability to develop and commercialize innovative therapies that address unmet needs in oncology.

Who Are MRTX's Key Customers?

• Cancer patients in need of targeted therapies.
• Oncologists and other healthcare professionals who prescribe cancer treatments.
• Hospitals and cancer centers that administer cancer therapies.
• Pharmaceutical companies that partner with Mirati to develop and commercialize its products.

Return on equity for Mirati Therapeutics, Inc. stands at -61.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -61.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.4%, the inverse of the P/E and a quick read on earnings relative to price.

Mirati Therapeutics, Inc. (MRTX) Valuation Context

Valued at $4.12B, MRTX is classified as a mid-cap stock.

Company Profile

Mirati Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Charles M. Baum. MRTX has traded publicly since 2013.

Mirati Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.58 places it in the safe zone, indicating low near-term bankruptcy risk.

Mirati Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.9% above estimates on average.

The most recent 12 insider filings for Mirati Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.5M shares disposed (about $3.4M), a signal worth weighing alongside the fundamentals.

MRTX Financials

MRTX Latest News

What Investors Ask About Mirati Therapeutics, Inc. (MRTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources